Όλο το DSpace

Εμφάνιση απλής εγγραφής

The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease

dc.creatorFousekis F.S., Papamichael K., Kourtis G., Albani E.N., Orfanidou A., Saridi M., Katsanos K.H., Christodoulou D.K.en
dc.date.accessioned2023-01-31T07:38:45Z
dc.date.available2023-01-31T07:38:45Z
dc.date.issued2022
dc.identifier10.20524/aog.2021.0682
dc.identifier.issn11087471
dc.identifier.urihttp://hdl.handle.net/11615/71757
dc.description.abstractThe development of biological agents against tumor necrosis factor (TNF) has revolutionized the management of inflammatory bowel disease (IBD), frequently achieving induction and maintenance of remission in both ulcerative colitis and Crohn’s disease. However, a loss of response due to the development of anti-drug antibodies (ADA) is seen annually in approximately 20% of IBD patients receiving anti-TNF therapy. Current evidence suggests that the use of immunomodulators (IMM), such as thiopurines (azathioprine and 6-mercaptopurine) or methotrexate, may prevent or suppress ADA formation. In this article, we present a comprehensive review of the available literature regarding the efficacy of IMM in the prevention and suppression of ADA development to anti-TNF therapy in patients with IBD. © 2022 Hellenic Society of Gastroenterology.en
dc.language.isoenen
dc.sourceAnnals of Gastroenterologyen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85125737651&doi=10.20524%2faog.2021.0682&partnerID=40&md5=1fc1b79cf6a627ea269c974b545718d9
dc.subjectadalimumaben
dc.subjectazathioprineen
dc.subjectbiosimilar agenten
dc.subjectcertolizumab pegolen
dc.subjectdrug antibodyen
dc.subjectgolimumaben
dc.subjectimmunomodulating agenten
dc.subjectinfliximaben
dc.subjectmercaptopurineen
dc.subjectmethotrexateen
dc.subjecttumor necrosis factor inhibitoren
dc.subjectCD4+ T lymphocyteen
dc.subjectcell proliferationen
dc.subjectclinical assessmenten
dc.subjectcoronavirus disease 2019en
dc.subjectCrohn diseaseen
dc.subjectdrug efficacyen
dc.subjectdrug safetyen
dc.subjecterythrocyte counten
dc.subjecthumanen
dc.subjectimmunogenicityen
dc.subjectinflammatory bowel diseaseen
dc.subjectlymphomaen
dc.subjectmemory B lymphocyteen
dc.subjectmulticenter study (topic)en
dc.subjectnon melanoma skin canceren
dc.subjectopportunistic infectionen
dc.subjectoutcome assessmenten
dc.subjectprevalenceen
dc.subjectrandomized controlled trial (topic)en
dc.subjectReviewen
dc.subjectsystematic reviewen
dc.subjecttreatment responseen
dc.subjecttuberculosisen
dc.subjectulcerative colitisen
dc.subjectHellenic Society of Gastroenterologyen
dc.titleThe efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel diseaseen
dc.typeotheren


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής